Abstract: Vaccine compositions comprising influenza antigens formulated as nanoparticulate water in oil miniemulsions. The vaccines may be formulated at the point of use and are useful in emergency response conditions.

Abstract: A safe and effective vaccine to prevent, slow, halt or reverse progression of Alzheimer's disease in human patients is disclosed. The vaccine includes A?1-42 or an beta amyloid self epitope (e.g. A?1-15, or other 7-mer or 15-mer peptide epitopes derived from A?1-42) conjugated to an immunogenic carrier formulated in a water-in-oil Th2-biased adjuvant/delivery system.

Abstract: Vaccine compositions comprising influenza antigens formulated as nanoparticulate water in oil miniemulsions. The vaccines may be formulated at the point of use and are useful in emergency response conditions.

Abstract: A safe and effective vaccine to prevent, slow, halt or reverse progression of Alzheimer's disease in human patients is disclosed. The vaccine includes A?1-42 or an beta amyloid self epitope (e.g. A?1-15, or other 7-mer or 15-mer peptide epitopes derived from A?1-42) conjugated to an immunogenic carrier (e.g. DT) formulated in a water-in-oil Th2-biased adjuvant/delivery system.

Abstract: A safe and effective vaccine to prevent, slow, halt or reverse progression of Alzheimer's disease in human patients is disclosed. The vaccine includes A?1-42 or an beta amyloid self epitope (e.g. A?1-15, or other 7-mer or 15-mer peptide epitopes derived from A?1-42) conjugated to an immunogenic carrier (e.g. DT) formulated in a water-in-oil Th2-biased adjuvant/delivery system.

Abstract: A safe and effective vaccine to prevent, slow, halt or reverse progression of Alzheimer's disease in human patients is disclosed. The vaccine includes A?1-42 or an beta amyloid self epitope (e.g. A?1-15, or other 7-mer or 15-mer peptide epitopes derived from A?1-42) conjugated to an immunogenic carrier (e.g. DT) formulated in a water-in-oil Th2-biased adjuvant/delivery system.

Abstract: A safe and effective vaccine to prevent, slow, halt or reverse progression of Alzheimer's disease in human patients is disclosed. The vaccine includes A?1-42 or an beta amyloid self epitope (e.g. A?1-15, or other 7-mer or 15-mer peptide epitopes derived from A?1-42) conjugated to an immunogenic carrier (e.g. DT) formulated in a water-in-oil Th2-biased adjuvant/delivery system.

Abstract: A safe and effective vaccine to prevent, slow, halt or reverse progression of Alzheimer's disease in human patients is disclosed. The vaccine includes A?1-42 or an beta amyloid self epitope (e.g. A?1-15, or other 7-mer or 15-mer peptide epitopes derived from A?1-42) conjugated to an immunogenic carrier (e.g. DT) formulated in a water-in-oil Th2-biased adjuvant/delivery system.

Abstract: A safe and effective vaccine to prevent, slow, halt or reverse progression of Alzheimer's disease in human patients is disclosed. The vaccine includes A?1-42 or an beta amyloid self epitope (e.g. A?1-15, or other 7-mer or 15-mer peptide epitopes derived from A?1-42) conjugated to an immunogenic carrier (e.g. DT) formulated in a water-in-oil Th2-biased adjuvant/delivery system.

Abstract: The present invention provides monoclonal antibodies (MAbs) selective for the N-termini and C-termini of the gastrin hormone forms, gastrin-17 (G17), glycine-extended gastrin-17 (G17-Gly), gastrin-34 (G34) and glycine-extended gastrin-34 (G34-Gly); and the hybridomas that produce these MAbs. Also provided are panels of MAbs useful for the detection and quantitation of gastrin-17 (G17), glycine-extended gastrin-17 (G17-Gly), gastrin-34 (G34) and glycine-extended gastrin-34 (G34-Gly). These assays are useful for monitoring a gastrin-mediated disease or condition, or for monitoring the progress of a course of therapy. The invention further provides solid phase assays including immunohistochemical (IHC) and immunofluorescence (IF) assays suitable for detection and visualization of gastrin species in solid samples, such as biopsy samples or tissue slices.

Abstract: The present invention provides progastrin-binding molecules that are useful therapeutically for passive immunization against progastrin in gastrin-promoted diseases or conditions. The progastrin-binding molecules are specific for progastrin but do not bind gastrin-17(G17), gastrin-34(G34), glycine-extended gastrin-17(G17-Gly) or glycine-extended gastrin-34(G34-Gly). The progastrin-binding molecules include monoclonal antibodies (MAbs) selective for sequences at the N-terminus and the C-terminus of the gastrin precursor molecule, progastrin.

Abstract: A combination for use in the treatment of pancreatic cancer comprising: (i) an anti-gastrin effective immunogenic composition; and, (ii) one or more chemotherapeutic agents suitable for inhibiting cancer growth.

Abstract: The present invention relates to a combination therapy method for treating gastrin-dependent tumors. The method comprises the immunization of a patient with an anti-gastrin 17 immunogenic composition in combination with the administration of chemotherapeutic agents such as 5-fluorouracil and leucovorin.

Abstract: Vaccine compositions comprising influenza antigens formulated as nanoparticulate water in oil miniemulsions. The vaccines may be formulated at the point of use and are useful in emergency response conditions.

Abstract: The present invention provides progastrin-binding molecules that are useful therapeutically for passive immunization against progastrin in gastrin-promoted diseases or conditions. The progastrin-binding molecules are specific for progastrin but do not bind gastrin-17(G17), gastrin-34(G34), glycine-extended gastrin-17(G17-Gly) or glycine-extended gastrin-34(G34-Gly). The progastrin-binding molecules include monoclonal antibodies (MAbs) selective for sequences at the N-terminus and the C-terminus of the gastrin precursor molecule, progastrin.

Abstract: The present invention provides progastrin-binding molecules specific for progastrin that do not bind gastrin-17(G17), gastrin-34(G34), glycine-extended gastrin-17(G17-Gly), or glycine-extended gastrin-34(G34-Gly). Further, the invention provides monoclonal antibodies (MAbs) selective for sequences at the N-terminus and the C-terminus of the gastrin precursor molecule, progastrin and the hybridomas that produce these MAbs. Also provided are panels of Mabs useful for the detection and quantitation of progastrin and gastrin hormone species in immuno-detection and quantitation assays. These assays are useful for diagnosing and monitoring a gastrin-promoted disease or condition, or for monitoring the progress of a course of therapy. The invention further provides solid phase assays including immunohistochemical (IHC) and immunofluorescence (IF) assays suitable for detection and visualization of gastrin species in solid samples, such as biopsy samples or tissue slices.

Abstract: A safe and effective vaccine to prevent, slow, halt or reverse progression of Alzheimer's disease in human patients is disclosed. The vaccine includes A?1-42 or an beta amyloid self epitope (e.g. A?1-15, or other 7-mer or 15-mer peptide epitopes derived from A?1-42) conjugated to an immunogenic carrier (e.g. DT) formulated in a water-in-oil Th2-biased adjuvant/delivery system.

Abstract: The invention provides assay methods for the detection and quantitation of gastrin hormones, including total and free gastrin hormone in a sample. ELISA-type heterogeneous phase assays suitable for use with biological fluid samples such as blood, plasma or other bodily fluids of a mammal, particularly a human subject are provided. The method provides a precise assay for the amounts of free and total G17 and G34 in biological fluid samples, as well as the amounts of free and total Gly-extended G17, and Gly-extended G34. Also provided are methods of determining suitable treatment for patient suffering from a gastrin hormone-mediated disease or condition employing gastrin hormone immunoassays.

Abstract: The invention relates to the treatment and/or prevention of cancerous and/or, precancerous conditions of the liver, lung and esophagus by actively and/or passively immunizing a patient against the peptide hormone gastrin and/or a gastrin receptor, e.g., the CCK-B/gastrin receptor. The immunizations of the invention may be employed as a monotherapy, an adjunctive therapy, or as part of a combination therapy.

Abstract: The present invention relates to a combination therapy method for treating gastrin-dependent tumors. The method comprises the immunization of a patient with an anti-gastrin 17 immunogenic composition in combination with the administration of chemotherapeutic agents such as 5-fluorouracil and leucovorin.